We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Highly Accurate Prognostic Test Predicts Personalized Risk of Severe Illness Due to SARS-CoV-2 Virus

By LabMedica International staff writers
Posted on 24 Mar 2021
A highly accurate prognostic test that predicts personalized risk of severe illness due to SARS-CoV-2 virus could become an important tool to manage the uncertainty of daily life during the pandemic by identifying high-risk individuals and for those that cannot be vaccinated.

Oxford BioDynamics Plc (Oxford, England) has launched its EpiSwitch COVID-19 Severity Test (CST), based on the company’s EpiSwitch 3D genomics platform. More...
Requiring only a routine blood draw, this important prognostic test is able to identify high-risk individuals who, if exposed to the SARS-CoV-2 virus, are likely to experience the most severe COVID-19 complications and will potentially require hospitalization and intensive care unit (ICU) support. This test is also relevant to manage care for those individuals who because they are immune-compromised/immune-suppressed or for other medical reasons cannot be vaccinated.

Standard available COVID-19 tests can only detect current or previous infection. They cannot predict immune response. EpiSwitch CST is a prognostic test which uses specific 3D genomic biomarkers to assess immune health and therefore can predict the likely severity of an individual’s COVID-19 response ahead of infection. People known to have a high risk of severe or critical disease may be able to benefit from increased infection mitigation, early aggressive medication, or early intervention in the event of infection. The score provided by the EpiSwitch CST will better enable physicians and at-risk individuals to form effective healthcare management plans, including making informed clinical decisions, lifestyle choices and workplace strategies.

The EpiSwitch CST is based on the findings of Oxford BioDynamics’ recently published, genome-wide study of COVID-positive patients, which identified key 3D genomic biomarkers that determine severity of COVID response. This precision medicine qPCR test was validated using international cohorts of COVID-19 patients from North America, South America and the UK, with the full spectrum of severities of response. It was shown to be robust for predicting critical (ICU) illness due to COVID-19, with high accuracy (92%), sensitivity (96%), specificity (86%), PPV (92%) and NPV (93%).

“As COVID-19 continues to have a major impact on us all, smarter, not just more, testing is required, to enable us to make informed decisions and manage our lives and livelihoods,” said Dr. Jon Burrows, CEO of Oxford BioDynamics. “Even with advanced national vaccination programs underway, millions of people (10 million in the US alone) remain exposed to the risk of severe COVID disease because they are immune-compromised/immune-suppressed or for other medical reasons cannot be vaccinated. Understanding their individual risk will enable them and their physicians to formulate a proactive healthcare plan, and ensure they take appropriate infection mitigation measures.”

Related Links:
Oxford BioDynamics Plc


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Collection and Transport System
PurSafe Plus®
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AiPlex VAS for the MosaiQ platform is designed to help reduce time-to-diagnosis for patients with autoimmune vasculitis (Photo courtesy of AliveDx)

Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis

Autoimmune vasculitis and related conditions are difficult to diagnose quickly and accurately, often requiring multiple tests to confirm the presence of specific autoantibodies. Traditional methods can... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.